Your browser doesn't support javascript.
Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study.
Mahamid, Mahmud; Nseir, Wiliam; Khoury, Tawfik; Mahamid, Baker; Nubania, Adi; Sub-Laban, Kamal; Schifter, Joel; Mari, Amir; Sbeit, Wisam; Goldin, Eran.
  • Mahamid M; Faculty of Medicine, Hebrew University of Jerusalem.
  • Nseir W; Department of gastroenterology and liver diseases, Shaare Zedek Medical Center, Jerusalem.
  • Khoury T; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Divisions of Internal Medicine, The Baruch Padeh Medical Center, Poriya.
  • Mahamid B; Department of Gastroenterology, Galilee Medical Center, Nahariya.
  • Nubania A; Faculty of Medicine in the Galilee, Bar-Ilan University, Safed.
  • Sub-Laban K; Gastroenterology and liver diseases unit, EMMS, the Nazareth Hospital, Nazareth, Israel.
  • Schifter J; Gastroenterology and liver diseases unit, EMMS, the Nazareth Hospital, Nazareth, Israel.
  • Mari A; Faculty of Medicine, Hebrew University of Jerusalem.
  • Sbeit W; Department of gastroenterology and liver diseases, Shaare Zedek Medical Center, Jerusalem.
  • Goldin E; Faculty of Medicine, Hebrew University of Jerusalem.
Eur J Gastroenterol Hepatol ; 33(12): 1578-1581, 2021 12 01.
Article in English | MEDLINE | ID: covidwho-1595632
ABSTRACT

AIM:

Coronavirus disease 2019 (COVID-19) is a recently encountered disease that was declared a pandemic by WHO in 2020. Obesity and other components of the metabolic syndrome may aggravate the severity of COVID-19. Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome. The aim of this study was to investigate a possible association between MAFLD and COVID-19 severity.

METHODS:

We performed a retrospective, case-control study, enrolling 71 consecutive COVID-19 patients who were divided into two groups according to the presence or absence of fatty liver by computed tomography scan. All medical records of eligible patients were reviewed including demographic, clinical, laboratory parameters and data regarding the presence of NAFLD and COVID-19 severity.

RESULTS:

NAFLD was identified in 22/71 (31%) of the study group. Out of 71, thirteen suffered from severe COVID-19. NAFLD patients had more severe COVID-19 compared with non-NAFLD subjects, 8/22 (36.3%) vs. 5/49(10.2%), (P < 0.005), respectively. Multiple logistic regression analysis showed that NAFLD subjects were more likely to have severe COVID-19 disease (odds ratio 3.57, 95% confidence interval 1.22, 14.48, P = 0.0031).

CONCLUSION:

NAFLD represents a high risk for severe COVID-19 irrespective to gender, and independent of metabolic syndrome specifically in male gender. Moreover, obesity, hypertension and metabolic syndrome were also significantly associated with severe COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Metabolic Syndrome / Non-alcoholic Fatty Liver Disease / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans / Male Language: English Journal: Eur J Gastroenterol Hepatol Journal subject: Gastroenterology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Metabolic Syndrome / Non-alcoholic Fatty Liver Disease / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans / Male Language: English Journal: Eur J Gastroenterol Hepatol Journal subject: Gastroenterology Year: 2021 Document Type: Article